The disclosure relates to uses of saccharide binding moieties, e.g., lectins for targeting cells, typically cancer stem cells. In certain embodiments, the disclosure relates to conjugates comprising: a) a saccharide binding moiety b) a polymer and c) a therapeutic agent wherein the saccharide binding protein is covalently attached to the polymer.